Total Valuation
Livzon Pharmaceutical Group has a market cap or net worth of €3.04B. The enterprise value is €17.84B.
Market Cap€3.04B
Enterprise Value€17.84B
Share Statistics
Livzon Pharmaceutical Group has 299,807,130 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding299,807,130
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Livzon Pharmaceutical Group’s return on equity (ROE) is 0.15 and return on invested capital (ROIC) is 12.50%.
Return on Equity (ROE)0.15
Return on Assets (ROA)0.08
Return on Invested Capital (ROIC)12.50%
Return on Capital Employed (ROCE)0.18
Revenue Per Employee1.35M
Profits Per Employee222.00K
Employee Count8,878
Asset Turnover0.50
Inventory Turnover2.62
Valuation Ratios
The current PE Ratio of Livzon Pharmaceutical Group is 16.3. Livzon Pharmaceutical Group’s PEG ratio is 8.43.
PE Ratio16.3
PS Ratio1.90
PB Ratio1.65
Price to FCF9.02
Price to Operating Cash Flow7.96
PEG Ratio8.43
Income Statement
In the last 12 months, Livzon Pharmaceutical Group had revenue of 12.02B and earned 2.02B in profits. Earnings per share was 2.27.
Revenue12.02B
Gross Profit7.92B
Operating Income2.95B
Pretax Income2.86B
Net Income2.02B
EBITDA3.10B
Earnings Per Share (EPS)2.27
Cash Flow
In the last 12 months, operating cash flow was 3.20B and capital expenditures -414.85M, giving a free cash flow of 2.79B billion.
Operating Cash Flow3.20B
Free Cash Flow2.79B
Free Cash Flow per Share9.30
Dividends & Yields
Livzon Pharmaceutical Group pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.34
52-Week Price Change-19.63%
50-Day Moving Average2.19
200-Day Moving Average2.52
Relative Strength Index (RSI)61.94
Average Volume (3m)5.00
Important Dates
Livzon Pharmaceutical Group upcoming earnings date is Mar 31, 2027, TBA (Confirmed).
Last Earnings DateOct 23, 2026
Next Earnings DateMar 31, 2027
Ex-Dividend Date―
Financial Position
Livzon Pharmaceutical Group as a current ratio of 2.23, with Debt / Equity ratio of 32.28%
Current Ratio2.23
Quick Ratio2.02
Debt to Market Cap0.17
Net Debt to EBITDA-1.76
Interest Coverage Ratio48.99
Taxes
In the past 12 months, Livzon Pharmaceutical Group has paid 451.01M in taxes.
Income Tax451.01M
Effective Tax Rate0.16
Enterprise Valuation
Livzon Pharmaceutical Group EV to EBITDA ratio is 5.63, with an EV/FCF ratio of 6.86.
EV to Sales1.45
EV to EBITDA5.63
EV to Free Cash Flow6.86
EV to Operating Cash Flow5.62
Balance Sheet
Livzon Pharmaceutical Group has €7.31B in cash and marketable securities with €4.20B in debt, giving a net cash position of €3.11B billion.
Cash & Marketable Securities€7.31B
Total Debt€4.20B
Net Cash€3.11B
Net Cash Per Share€10.38
Tangible Book Value Per Share€16.61
Margins
Gross margin is 60.53%, with operating margin of 24.51%, and net profit margin of 16.83%.
Gross Margin60.53%
Operating Margin24.51%
Pretax Margin23.81%
Net Profit Margin16.83%
EBITDA Margin25.75%
EBIT Margin21.85%
Analyst Forecast
The average price target for Livzon Pharmaceutical Group is €4.20, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target€4.20
Price Target Upside80.97% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast-14.39%
EPS Growth Forecast-27.35%